Variables | Cirrhotic patients without HCC (n = 696) | Cirrhotic patients with HCC (n = 35) | p |
---|---|---|---|
Male gender, n (%) | 367 (52.7) | 24 (70.6) | 0.04 |
Age, years, ≥ 67, n (%) | 373 (53.6) | 23 (67.6) | 0.11 |
BMI, kg/m2 ≥ 26, n (%) | 285 (51.4) | 14 (42.4) | 0.32 |
Presence of diabetes, n (%) | 89 (12.8) | 10 (29.4) | 0.006 |
CTP B class, n (%) | 72 (10.3) | 10 (29.4) | 0.001 |
HCV genotype 1, n (%) | 524 (76.2) | 28 (82.4) | 0.41 |
24 weeks treatment duration, n (%) | 311 (44.6) | 19 (55.9) | 0.19 |
Baseline HCV-RNA, UI/ml, ≥ 1 × 106, n (%) | 381 (54.7) | 13 (38.2) | 0.06 |
Liver stiffness, kPa ≥ 20, n (%) | 176 (49.7) | 24 (72.7) | 0.01 |
SVR12, n (%) | 682 (97.8) | 32 (94.1) | 0.16 |
DAA-SOF based, n (%) | 555 (79.6) | 30 (88.2) | 0.31 |
DAA-RBV included, n (%) | 535 (76.8) | 15 (44.1) | < 0.0001 |
DAA-SOF + RBV, n (%) | 438 (63.0) | 12 (35.3) | 0.001 |
DAA-SOF without RBV, n (%) | 113 (16.2) | 18 (52.9) | < 0.0001 |